Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a ...

On February 3 rd, the company announced that it had completed its acquisition of Ambry Genetics, a genetic testing company that strives to improve health by understanding the relationship between ...

Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market share gains following Invitae’s bankruptcy.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. About Tempus Tempus is a ...